Previous Close | 8.41 |
Open | 8.40 |
Bid | 7.44 x 1100 |
Ask | 8.50 x 900 |
Day's Range | 8.39 - 8.51 |
52 Week Range | 6.10 - 8.89 |
Volume | 91,897 |
Avg. Volume | 159,112 |
Market Cap | 281.234M |
Beta (3Y Monthly) | 0.40 |
PE Ratio (TTM) | 4.27 |
EPS (TTM) | 1.98 |
Earnings Date | Mar 13, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.75 |
Apyx Medical Corporation, formerly Bovie Medical Corporation, (APYX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced that financial results for the fourth quarter and fiscal year 2018 will be released after the market closes on Wednesday, March 13. To listen to the call by phone, interested parties may dial 844-507-6493 (or 647-253-8641 for international callers) and provide access code 5488443. Participants should ask for the Apyx Medical Corporation Call.
Zimmer Biomet (ZBH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Is (APYX) Outperforming Other Medical Stocks This Year?
Does Bovie Medical (APYX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Apyx Medical Corporation, formerly Bovie Medical Corporation, (APYX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced that Todd Hornsby has been promoted to Executive Vice President, effective January 2, 2019. Mr. Hornsby joined Apyx Medical in August, 2014, and held the position of Vice President and General Manager of Advanced Energy prior to his promotion. “Todd has done an excellent job leading the global sales and marketing efforts for our Advanced Energy business, specifically the commercialization of our Renuvion Cosmetic Technology in the U.S. cosmetic surgery market and in an increasing number of international markets as well,” said Charlie Goodwin, President and Chief Executive Officer.
Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today reported preliminary revenue results for the full year and fourth quarter ended December 31, 2018.